Thanks for sharing and interpreting it for us. Unfortunate for the patients who died or had adverse impacts (one patient who died had Covid which would likely be not treatment related). Despite such a poor response why would J&J be presenting/ accepted by ASCO to present at such a prestigious event?
Despite the poor results their HREC is continuing the trials for patients who want to continue treatment despite knowing the interim results - should we interpret it as a serious lack of alternatives?
CU6 - Media and Industry News, page-145
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.37 |
Change
0.300(5.92%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $5.10 | $5.39 | $5.10 | $4.873M | 937.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 4635 | $5.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.38 | 2143 | 9 |
View Market Depth
| Last trade - 13.44pm 28/06/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |